Description: Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. The Company is utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibrocell’s pipeline of localized gene therapy candidates include FCX-007 for the treatment of RDEB, a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U. S. Food and Drug Administration. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Business Profile
